253 related articles for article (PubMed ID: 29926157)
1. The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
Ricchi P; Meloni A; Pistoia L; Spasiano A; Spiga A; Allò M; Gamberini MR; Lisi R; Campisi S; Peluso A; Missere M; Renne S; Mangione M; Positano V; Pepe A
Ann Hematol; 2018 Oct; 97(10):1925-1932. PubMed ID: 29926157
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
3. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
4. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
5. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
[TBL] [Abstract][Full Text] [Related]
6. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
[TBL] [Abstract][Full Text] [Related]
8. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
9. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
[TBL] [Abstract][Full Text] [Related]
10. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
11. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
14. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
15. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cardiac iron overload by optimising iron chelation therapy in transfusion dependent thalassaemia using cardiac T2* MRI: a quality improvement project from Pakistan.
Hussain S; Hoodbhoy Z; Ali F; Hasan E; Alvi N; Hussain A; Ishrat K; Ur Rahman Z; Qamruddin A; Parvin A; Hasan BS
Arch Dis Child; 2020 Nov; 105(11):1041-1048. PubMed ID: 32994214
[TBL] [Abstract][Full Text] [Related]
17. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
18. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
[TBL] [Abstract][Full Text] [Related]
19. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]